B7H3/PDL1 BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF

Abstract

The present invention relates to a B7H3/PDL1 bispecific antibody, and a pharmaceutical composition comprising same and a use thereof. The bispecific antibody can bind to B7H3 and PDL1 in a targeted manner, and comprises: a monoclonal antibody unit, targeting PDL1 and comprising two heavy chains and two light chains; and a nano-antibody unit, targeting B7H3 and comprising two identical nano-antibodies, wherein the C-terminuses of the two nano-antibodies are respectively linked to the C-terminuses of the Fc fragments of the two heavy chains of the monoclonal antibody unit by means of a linker peptide. The bispecific antibody of the present invention can bind to both B7H3 and PDL1, can relieve inhibition of T cells by PDL1 while targeting tumor cells, and shows anti-tumor activity superior to that of a drug combination using a monoclonal antibody.

CPC Classifications